Welcome to our dedicated page for Barinthus Biotherapeutics plc SEC filings (Ticker: BRNS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Barinthus Biotherapeutics plc’s disclosures blend clinical jargon with complex accounting. If you’ve tried to decode vector technology, cash-runway tables, or pivotal-trial milestones, you understand the challenge—and why searches like “Barinthus Biotherapeutics SEC filings explained simply” are common. Even seasoned analysts can lose key details about ChAdOx platform progress or SNAP-TI safety updates buried deep in footnotes.
Need instant visibility into Barinthus Biotherapeutics insider trading Form 4 transactions? Stock Titan’s AI turns every Barinthus Biotherapeutics quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained into concise takeaways the moment they post to EDGAR. Real-time alerts surface Barinthus Biotherapeutics Form 4 insider transactions real-time and executive stock transactions Form 4, while interactive dashboards layer Barinthus Biotherapeutics earnings report filing analysis over historical data for quick trend checks.
From pipeline spend by indication to dilution forecasts ahead of the next Barinthus Biotherapeutics proxy statement executive compensation vote, our platform keeps biotech-specific metrics front and center. Start understanding Barinthus Biotherapeutics SEC documents with AI, monitor cash-burn trajectories, or compare R&D outlays quarter over quarter—without wading through hundreds of pages. Stock Titan highlights what matters so you can focus on investment decisions rather than document hunts.
Barinthus Biotherapeutics plc filed an Amendment No. 1 to its Current Report to correct an inaccurate statement that had appeared in Exhibit 99.1. The correction relates to a sub-bullet describing the Phase 1 trial result for VTP-850 in patients with prostate cancer. The company states no other changes were made to the original report.
The Original Report also furnished a press release providing an overview and announcing financial results for the quarter ended June 30, 2025; that Item 2.02 information is furnished but expressly not deemed "filed" for Section 18 purposes and is not incorporated by reference.
Q2-25 snapshot: Barinthus Biotherapeutics (BRNS) posted a net loss of $21.1 million (-24.6 % YoY) or -$0.52/sh; six-month loss widened to $40.8 million. Cash & equivalents fell to $86.3 million from $110.7 million at FY-24, but management still forecasts liquidity into early-2027.
Expense trends: R&D dropped 32 % YoY to $8.0 million as infectious-disease and oncology projects were shelved; however, G&A more than doubled to $15.4 million due mainly to an $8.0 million foreign-exchange loss and restructuring costs, lifting total operating spend 24 % to $23.3 million.
Balance sheet & risk: Current assets declined 20 % to $100.4 million; equity slid to $102.5 million. There is no debt, but cash burn averaged ~$17 million per quarter, and accumulated deficit reached $278.4 million.
Pipeline focus: Strategy now centres on immunology & inflammation. Lead SNAP-TI asset VTP-1000 (celiac disease) has completed dosing of two single-ascending-dose cohorts; topline safety/biomarker data expected early Q4-25. VTP-300 (HBV) will finish current Phase 2 trials while partnering options are explored; CEPI-funded MERS vaccine program is being exited.
Key watch-points: 1) VTP-1000 Phase 1 read-out, 2) ability to rein in G&A, 3) partnership progress for VTP-300, and 4) sustaining cash runway under current burn.
FAQ
What is the current stock price of Barinthus Biotherapeutics plc (BRNS)?
What is the market cap of Barinthus Biotherapeutics plc (BRNS)?
